How else can you sell 10M? - 500,000 each day on market (share...

How else can you sell 10M?

- 500,000 each day on market (share price would have dived)
- SPP to retail (complex and costly)
- at a premium to institutions (any buyer would want immediate leverage)

The price and timing might have been under negotiation for a number of weeks.

I would assume Regal are offloading some at a tidy short term profit (25%), but the encouraging thing is the share price doesn't seem to have suffered since this announcement.

My assumption on the sale is that Swinnerton may feel he's ready to move on. The R&D, software development and platform is now at scale. He's at arms length being based in the US and the new additions to the team (including board) are highly skilled managers with enterprise experience in international healthcare and tech organisations. Swinnerton may be looking forward, knowing he curated an idea to a listed, $100M MC company. He is an entrepreneur with a development background, not a gun for hire who takes a magnifying glass looking for mergers and acquisitions.

Re: the comment regarding outgoings. I would guess from all the peers including RAP, PCK, COO, ALC, M7T, 1ST etc, MedAdvisor is likely to have the highest headcount. But out of all those listed, MedAdvisor has had the most financial support from international healthcare investors - EBOS coming onboard a couple years ago and HMS last year.

Once there's momentum and revenue from the Adheris programs in the US, the Zuellig partners in Asia and the UK pharmacies through NPA, the market should see these first customers and pilots trigger larger and longer contracts. With all of this to happen over the next 6 months I continue to be cautiously optimistic that we'll see the share price at $1 at the end of 2020 and (staff) outgoings will be similar to now.